Cencora, Inc. reported fourth-quarter fiscal 2026 revenue of $88.4 billion, a 5.5 percent increase year-over-year, driven by growth in U.S. Healthcare Solutions and International Healthcare Solutions segments. GAAP diluted earnings per share were $2.71 compared to a loss of $1.75 in the prior year period, while adjusted diluted EPS rose 21.4 percent to $4.66. For the full fiscal year, revenue reached $337.4 billion with adjusted diluted EPS increasing 12.3 percent to $17.97. The company also announced a 10 percent increase in its quarterly dividend to $0.66 per share, payable November 30, 2026, and provided fiscal 2027 adjusted diluted EPS guidance of $19.40 to $19.75. Cencora operates as a leading global pharmaceutical solutions organization providing distribution and specialty services.
